MDNAF
Price
$0.63
Change
-$0.03 (-4.55%)
Updated
Feb 3 closing price
Capitalization
53.06M
8 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$7.50
Change
-$0.17 (-2.21%)
Updated
Feb 4, 04:59 PM (EDT)
Capitalization
1.07B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDNAF vs VIR

Header iconMDNAF vs VIR Comparison
Open Charts MDNAF vs VIRBanner chart's image
Medicenna Therapeutics
Price$0.63
Change-$0.03 (-4.55%)
Volume$96.86K
Capitalization53.06M
Vir Biotechnology
Price$7.50
Change-$0.17 (-2.21%)
Volume$53.05K
Capitalization1.07B
MDNAF vs VIR Comparison Chart in %
View a ticker or compare two or three
VS
MDNAF vs. VIR commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDNAF is a Hold and VIR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (MDNAF: $0.63 vs. VIR: $7.68)
Brand notoriety: MDNAF and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDNAF: 71% vs. VIR: 54%
Market capitalization -- MDNAF: $53.06M vs. VIR: $1.07B
MDNAF [@Biotechnology] is valued at $53.06M. VIR’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDNAF’s FA Score shows that 0 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • MDNAF’s FA Score: 0 green, 5 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, VIR is a better buy in the long-term than MDNAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDNAF’s TA Score shows that 4 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).

  • MDNAF’s TA Score: 4 bullish, 3 bearish.
  • VIR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VIR is a better buy in the short-term than MDNAF.

Price Growth

MDNAF (@Biotechnology) experienced а -3.23% price change this week, while VIR (@Biotechnology) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.56%. For the same industry, the average monthly price growth was +1.40%, and the average quarterly price growth was +33.10%.

Reported Earning Dates

MDNAF is expected to report earnings on Feb 12, 2026.

VIR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-2.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VIR($1.07B) has a higher market cap than MDNAF($53.1M). VIR YTD gains are higher at: 27.363 vs. MDNAF (-6.980). MDNAF has higher annual earnings (EBITDA): -21.74M vs. VIR (-541.01M). VIR has more cash in the bank: 507M vs. MDNAF (15.7M). MDNAF has less debt than VIR: MDNAF (149K) vs VIR (100M). VIR has higher revenues than MDNAF: VIR (14M) vs MDNAF (0).
MDNAFVIRMDNAF / VIR
Capitalization53.1M1.07B5%
EBITDA-21.74M-541.01M4%
Gain YTD-6.98027.363-26%
P/E RatioN/AN/A-
Revenue014M-
Total Cash15.7M507M3%
Total Debt149K100M0%
FUNDAMENTALS RATINGS
MDNAF vs VIR: Fundamental Ratings
MDNAF
VIR
OUTLOOK RATING
1..100
214
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
8439
P/E GROWTH RATING
1..100
10030
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDNAF's Valuation (42) in the null industry is in the same range as VIR (53). This means that MDNAF’s stock grew similarly to VIR’s over the last 12 months.

MDNAF's Profit vs Risk Rating (100) in the null industry is in the same range as VIR (100). This means that MDNAF’s stock grew similarly to VIR’s over the last 12 months.

VIR's SMR Rating (97) in the null industry is in the same range as MDNAF (99). This means that VIR’s stock grew similarly to MDNAF’s over the last 12 months.

VIR's Price Growth Rating (39) in the null industry is somewhat better than the same rating for MDNAF (84). This means that VIR’s stock grew somewhat faster than MDNAF’s over the last 12 months.

VIR's P/E Growth Rating (30) in the null industry is significantly better than the same rating for MDNAF (100). This means that VIR’s stock grew significantly faster than MDNAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDNAFVIR
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 13 days ago
73%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
MDNAF
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMBVF11.42N/A
N/A
Arca Continental SAB de CV
CUCSF0.63N/A
N/A
China Communications Services Corp., Ltd.
DCHIY1.51N/A
N/A
Digital China Holdings Ltd.
EBZT0.10N/A
-1.96%
Everything Blockchain, Inc.
BLMWF1.00-0.03
-3.10%
BluMetric Environmental, Inc.

MDNAF and

Correlation & Price change

A.I.dvisor tells us that MDNAF and LRMR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDNAF and LRMR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDNAF
1D Price
Change %
MDNAF100%
-3.17%
LRMR - MDNAF
25%
Poorly correlated
-1.71%
VIR - MDNAF
25%
Poorly correlated
-0.39%
STOK - MDNAF
23%
Poorly correlated
+9.81%
CGEM - MDNAF
23%
Poorly correlated
+3.93%
PTCT - MDNAF
22%
Poorly correlated
-0.07%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with RLAY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-0.39%
RLAY - VIR
57%
Loosely correlated
+6.38%
CLDX - VIR
56%
Loosely correlated
+2.07%
NRIX - VIR
53%
Loosely correlated
-1.76%
CRBU - VIR
52%
Loosely correlated
+6.85%
SANA - VIR
51%
Loosely correlated
-3.92%
More